The National Institutes of Health (NIH) Sexual & Gender Minority Research Office Request for Letters of Intent for Inaugural Investigator Award Program, 14870-14871 [2018-07066]
Download as PDF
<![CDATA[
daltland on DSKBBV9HB2PROD with NOTICES
14870
Federal Register / Vol. 83, No. 67 / Friday, April 6, 2018 / Notices
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W602, Bethesda, MD
20892–9750, 240–276–6456, tangd@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Cancer
Epidemiology Cohorts—Infrastructure and
Research.
Date: June 6, 2018.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W612, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Shari W. Campbell, DPM,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W612,
Bethesda, MD 20892–9750, 240–276–7381,
shari.campbell@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–8A:
NCI Clinical and Translational R21.
Date: June 12, 2018.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W238, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Jeffrey E. DeClue, Ph.D.,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W238,
Bethesda, MD 20892–9750, 240–276–6371,
decluej@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–8B:
NCI Omnibus R03.
Date: June 19, 2018.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W238, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Jeffrey E. DeClue, Ph.D.,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH
9609, Medical Center Drive, Room 7W238,
Bethesda, MD 20892–9750, 240–276–6371,
decluej@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
VerDate Sep<11>2014
19:21 Apr 05, 2018
Jkt 244001
Dated: April 3, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–07058 Filed 4–5–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
The National Institutes of Health (NIH)
Sexual & Gender Minority Research
Office Request for Letters of Intent for
Inaugural Investigator Award Program
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice; call for Letters of Intent.
The National Institutes of
Health (NIH) Sexual & Gender Minority
Research Office (SGMRO) is requesting
letters of intent for an inaugural
Investigator Award Program. The NIH
Sexual and Gender Minority (SGM)
Investigator Award Program was
developed to recognize early-stage
investigators who have made
substantial, outstanding research
contributions in areas related to SGM
health and who are poised to become
future leaders or are already leading the
field of SGM health research. The NIH
SGMRO is currently soliciting
nominations for the 2018 NIH SGM
Investigator Awards.
DATES: Notices of intent to apply due
April 20, 2018 and final nominations
due May 18, 2018.
FOR FURTHER INFORMATION CONTACT:
Karen Parker, Ph.D., Director, Sexual &
Gender Minority Research Office
(SGMRO), 1 Center Drive, Building 1,
Room 257, Bethesda, MD 20892,
klparker@mail.nih.gov, 301–451–2055.
SUPPLEMENTARY INFORMATION: ‘‘Sexual
and gender minority’’ is an umbrella
term that encompasses lesbian, gay,
bisexual, and transgender populations
as well as those whose sexual
orientation, gender identity and
expressions, or reproductive
development varies from traditional,
societal, cultural, or physiological
norms.
The Sexual and Gender Minority
Research Office (SGMRO) coordinates
sexual and gender minority (SGM)–
related research and activities by
working directly with the NIH
Institutes, Centers, and Offices. The
Office was officially established in
September 2015 within the NIH
Division of Program Coordination,
Planning, and Strategic Initiatives
(DPCPSI).
SUMMARY:
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
The SGMRO has the following
research-related goals: (1) Expand the
knowledge base of SGM health and
well-being through NIH-supported
research; (2) Remove barriers to
planning, conducting, and reporting
NIH-supported research about SGM
health and well-being; (3) Strengthen
the community of researchers and
scholars who conduct research relevant
to SGM health and well-being; and (4)
Evaluate progress on advancing SGM
research.
2018 Award Details
Two non-monetary awards of
recognition will be offered to early stage
investigators who demonstrate both
contemporary achievement in and a
commitment to an area of SGM-related
health research. The award winners will
be invited, with all travel expenses
covered (limited to reimbursement
based on Federal Travel Regulations and
HHS and NIH guidance), to give a
lecture at the NIH on September 6, 2018.
This event will be webcast live and the
presentations will be archived and
available for future viewing.
Eligibility Criteria
The following individuals are not
eligible to be nominated: Federal
employees and interns; federal
contractors; and members of the NIH
SGM Research Working Group.
• At the time of the nomination due
date, May 11, the candidate must meet
the NIH’s definitions of an early stage
investigator (ESI) (https://
grants.nih.gov/grants/guide/notice-files/
NOT-OD-17-101.html).
Letters of Intent
A Letter of Intent (LOI) to submit a
nomination is required (nominees may
self-nominate and submit their own
LOIs). The LOI should be a 1-page,
single-spaced Word or PDF document
and include:
1. Nominee’s name, title, affiliation,
and date of terminal degree.
2. eRA Commons ID.
a. Before submitting the LOI,
researchers should confirm ESI status is
correctly marked in their eRA Commons
(https://era.nih.gov/) profile. If the
status is incorrect, please contact the
NIH eRA Service Desk (https://
grants.nih.gov/support/) to
resolve the issue before submitting an
LOI.
3. SGM research focus of nominee’s
work.
Attach the LOI (as a Word or PDF
document) to an email and send it to
sgmhealthresearch@od.nih.gov with the
subject line ‘‘2018 SGM Investigator
E:\FR\FM\06APN1.SGM
06APN1
Federal Register / Vol. 83, No. 67 / Friday, April 6, 2018 / Notices
Award Letter of Intent’’ no later than
11:59 p.m. on April 20, 2018.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Nominations
Substance Abuse and Mental Health
Services Administration
Nomination packages may be
submitted by the nominee or a
nominee’s mentor or colleague.
Nomination packages must be a single
PDF file that includes:
1. NIH Biosketch including a link
(URL) to the nominee’s My Bibliography
in PubMed.
a. If you do not have a My
Bibliography in PubMed, refer to these
simple step-by-step instructions to save
your citations in PubMed to a ‘‘My
Bibliography.’’
b. Use the URL that PubMed
automatically generates when you
change your ‘‘My Bibliography’’ sharing
setting to public.
2. Letter of nomination (1,000 words
or less) from a mentor or colleague
familiar with the nominee’s work,
addressing the nominee’s innovative
contribution to the field of SGM health
research, crosscutting and collaborative
nature of that research, trajectory of
career development, and leadership
strengths. The strongest letters will
demonstrate the lasting significance and
impact of the nominee’s work to date.
3. Two letters of endorsement from
other mentors or colleagues. Letters of
endorsement may be less encompassing
than the letter of nomination, but
should address similar themes.
4. A PDF of a key, peer-reviewed
article published in the past 24-month
period, which is first-authored by the
nominee. If in press, please provide the
accepted paper and the letter of
acceptance from the journal.
After compiling all the above
elements into a single PDF file, attach
the PDF to an email, and send it to
sgmhealthresearch@od.nih.gov with the
subject line header ‘‘2018 SGM
Investigator Award Nomination’’ no
later than 11:59 p.m. on May 18, 2018.
daltland on DSKBBV9HB2PROD with NOTICES
Review and Selection Process
• Stage 1: The SGMRO will assemble
a review panel composed of NIH staff
with relevant expertise. This panel will
provide recommendations to the
SGMRO Director and the DPCPSI
Director on awardees.
• Stage 2: The SGMRO and DPCPSI
Directors will review the
recommendations and select the final
awardees.
Dated: March 8, 2018.
Lawrence A. Tabak,
Deputy Director, National Institutes of Health.
[FR Doc. 2018–07066 Filed 4–5–18; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
19:21 Apr 05, 2018
Jkt 244001
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: Networking Suicide Prevention
Hotlines—Evaluation of Imminent Risk
(OMB No. 0930–0333)—REVISION
The Substance Abuse and Mental
Health Services Administration’s
(SAMHSA), Center for Mental Health
Services (CMHS) funds a National
Suicide Prevention Lifeline Network
(‘‘Lifeline’’), consisting of a toll-free
telephone number that routes calls from
anywhere in the United States to a
network of local crisis centers. In turn,
the local centers link callers to local
emergency, mental health, and social
service resources. This project is a
revision of the Evaluation of Imminent
Risk and builds on previously approved
data collection activities [Evaluation of
Networking Suicide Prevention Hotlines
Follow-Up Assessment (OMB No. 0930–
0274) and Call Monitoring of National
Suicide Prevention Lifeline Form (OMB
No. 0930–0275)]. The extension data
collection is an effort to advance the
understanding of crisis hotline
utilization and its impact.
The overarching purpose of the
proposed Evaluation of Imminent Risk
data collection is to evaluate hotline
counselors’ management of imminent
risk callers and third party callers
concerned about persons at imminent
risk, assess counselor adherence to the
Lifeline Policies and Guidelines for
Helping Callers at Imminent Risk of
Suicide, and identify the types of
interventions implemented with
imminent risk callers. Specifically, the
Evaluation of Imminent Risk will collect
data, using the Imminent Risk FormRevised, to inform the network’s
knowledge of the extent to which
counselors are aware of and being
guided by Lifeline’s imminent risk
guidelines; counselors’ definitions of
imminent risk; the rates of active rescue
of imminent risk callers; the types of
rescue and non-rescue interventions
used; barriers to intervention; and the
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
14871
circumstances in which active rescue is
initiated, including the caller’s
agreement to receive the intervention.
To capture differences across centers,
the form also collects information on
counselors’ employment status and
hours worked/volunteered, level of
education, license status, training status,
source of safety planning protocols, and
responsibility for follow up.
Clearance is being requested for one
activity to assess the knowledge,
actions, and practices of counselors to
aid callers who are determined to be at
imminent risk for suicide and who may
require active rescue. This evaluation
will allow researchers to examine and
understand the actions taken by
counselors to aid imminent risk callers,
the need for active rescue, the types of
interventions used, and, ultimately,
improve the delivery of crisis hotline
services to imminent risk callers. A total
of seven centers will participate in this
evaluation. Thus, SAMHSA is
requesting OMB review and approval of
the Imminent Risk Form-Revised.
Crisis counselors at seven
participating centers will record
information discussed with imminent
risk callers on the Imminent Risk FormRevised, which does not require direct
data collection from callers. As with
previously approved evaluations, callers
will maintain anonymity. Participating
counselors will be asked to complete the
form for 100% of their imminent risk
calls. At centers with high call volumes,
data collection may be limited to
designated shifts. This form requests
information in 15 content areas, each
with multiple sub-items and response
options. Response options include
open-ended, yes/no, Likert-type ratings,
and multiple choice/check all that
apply. The form also requests
demographic information on the caller,
the identification of the center and
counselor submitting the form, and the
date of the call. Specifically, the form is
divided into the following sections: (1)
Counselor information, (2) center
information, (3) call characteristics (e.g.,
line called, language spoken,
participation of third party), (4) suicidal
desire, (5) suicidal intent, (6) suicidal
capability, (7) buffers to suicide, (8)
interventions agreed to by caller or
implemented by counselor without
caller’s consent, (9) whether imminent
risk was reduced enough such that
active rescue was not needed, (10)
interventions for third party callers
calling about a person at imminent risk,
(11) whether supervisory consultation
occurred during or after the call, (12)
barriers to getting needed help to the
person at imminent risk, (13) steps
taken to confirm whether emergency
E:\FR\FM\06APN1.SGM
06APN1
]]>Agencies
[Federal Register Volume 83, Number 67 (Friday, April 6, 2018)]
[Notices]
[Pages 14870-14871]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-07066]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
The National Institutes of Health (NIH) Sexual & Gender Minority
Research Office Request for Letters of Intent for Inaugural
Investigator Award Program
AGENCY: National Institutes of Health, HHS.
ACTION: Notice; call for Letters of Intent.
-----------------------------------------------------------------------
SUMMARY: The National Institutes of Health (NIH) Sexual & Gender
Minority Research Office (SGMRO) is requesting letters of intent for an
inaugural Investigator Award Program. The NIH Sexual and Gender
Minority (SGM) Investigator Award Program was developed to recognize
early-stage investigators who have made substantial, outstanding
research contributions in areas related to SGM health and who are
poised to become future leaders or are already leading the field of SGM
health research. The NIH SGMRO is currently soliciting nominations for
the 2018 NIH SGM Investigator Awards.
DATES: Notices of intent to apply due April 20, 2018 and final
nominations due May 18, 2018.
FOR FURTHER INFORMATION CONTACT: Karen Parker, Ph.D., Director, Sexual
& Gender Minority Research Office (SGMRO), 1 Center Drive, Building 1,
Room 257, Bethesda, MD 20892, [email protected], 301-451-2055.
SUPPLEMENTARY INFORMATION: ``Sexual and gender minority'' is an
umbrella term that encompasses lesbian, gay, bisexual, and transgender
populations as well as those whose sexual orientation, gender identity
and expressions, or reproductive development varies from traditional,
societal, cultural, or physiological norms.
The Sexual and Gender Minority Research Office (SGMRO) coordinates
sexual and gender minority (SGM)-related research and activities by
working directly with the NIH Institutes, Centers, and Offices. The
Office was officially established in September 2015 within the NIH
Division of Program Coordination, Planning, and Strategic Initiatives
(DPCPSI).
The SGMRO has the following research-related goals: (1) Expand the
knowledge base of SGM health and well-being through NIH-supported
research; (2) Remove barriers to planning, conducting, and reporting
NIH-supported research about SGM health and well-being; (3) Strengthen
the community of researchers and scholars who conduct research relevant
to SGM health and well-being; and (4) Evaluate progress on advancing
SGM research.
2018 Award Details
Two non-monetary awards of recognition will be offered to early
stage investigators who demonstrate both contemporary achievement in
and a commitment to an area of SGM-related health research. The award
winners will be invited, with all travel expenses covered (limited to
reimbursement based on Federal Travel Regulations and HHS and NIH
guidance), to give a lecture at the NIH on September 6, 2018. This
event will be webcast live and the presentations will be archived and
available for future viewing.
Eligibility Criteria
The following individuals are not eligible to be nominated: Federal
employees and interns; federal contractors; and members of the NIH SGM
Research Working Group.
At the time of the nomination due date, May 11, the
candidate must meet the NIH's definitions of an early stage
investigator (ESI) (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-101.html).
Letters of Intent
A Letter of Intent (LOI) to submit a nomination is required
(nominees may self-nominate and submit their own LOIs). The LOI should
be a 1-page, single-spaced Word or PDF document and include:
1. Nominee's name, title, affiliation, and date of terminal degree.
2. eRA Commons ID.
a. Before submitting the LOI, researchers should confirm ESI status
is correctly marked in their eRA Commons (https://era.nih.gov/)
profile. If the status is incorrect, please contact the NIH eRA Service
Desk (https://grants.nih.gov/support/) to resolve the issue
before submitting an LOI.
3. SGM research focus of nominee's work.
Attach the LOI (as a Word or PDF document) to an email and send it
to [email protected] with the subject line ``2018 SGM
Investigator
[[Page 14871]]
Award Letter of Intent'' no later than 11:59 p.m. on April 20, 2018.
Nominations
Nomination packages may be submitted by the nominee or a nominee's
mentor or colleague. Nomination packages must be a single PDF file that
includes:
1. NIH Biosketch including a link (URL) to the nominee's My
Bibliography in PubMed.
a. If you do not have a My Bibliography in PubMed, refer to these
simple step-by-step instructions to save your citations in PubMed to a
``My Bibliography.''
b. Use the URL that PubMed automatically generates when you change
your ``My Bibliography'' sharing setting to public.
2. Letter of nomination (1,000 words or less) from a mentor or
colleague familiar with the nominee's work, addressing the nominee's
innovative contribution to the field of SGM health research,
crosscutting and collaborative nature of that research, trajectory of
career development, and leadership strengths. The strongest letters
will demonstrate the lasting significance and impact of the nominee's
work to date.
3. Two letters of endorsement from other mentors or colleagues.
Letters of endorsement may be less encompassing than the letter of
nomination, but should address similar themes.
4. A PDF of a key, peer-reviewed article published in the past 24-
month period, which is first-authored by the nominee. If in press,
please provide the accepted paper and the letter of acceptance from the
journal.
After compiling all the above elements into a single PDF file,
attach the PDF to an email, and send it to [email protected]
with the subject line header ``2018 SGM Investigator Award Nomination''
no later than 11:59 p.m. on May 18, 2018.
Review and Selection Process
Stage 1: The SGMRO will assemble a review panel composed
of NIH staff with relevant expertise. This panel will provide
recommendations to the SGMRO Director and the DPCPSI Director on
awardees.
Stage 2: The SGMRO and DPCPSI Directors will review the
recommendations and select the final awardees.
Dated: March 8, 2018.
Lawrence A. Tabak,
Deputy Director, National Institutes of Health.
[FR Doc. 2018-07066 Filed 4-5-18; 8:45 am]
BILLING CODE 4140-01-P
